Fagron (FAGR.BR) Stock Price

Fagron Price

Euronext Brussels·CLOSED
22.35EUR-0.10 (-0.45 %)
Market closed

Revenue has compounded at 6.7% per year over the past 19 years to 952.17 M EUR. Earnings per share have grown at 5.5% per year over the last 19 years. Fagron's net margin stands at 9.6%, down from 10.6% several years earlier. Fagron currently offers a dividend yield of about 1.57%. The payout ratio is around 28% of earnings. The dividend has grown at 10.9% per year over the past 17 years. Analysts set a median price target of 27.54 EUR, implying 23.2% above the current price. Of 13 analysts, 12 rate the stock a buy — an overall Buy consensus. The stock trades about 14% above its 52-week low.

Fagron stock price

Volume
Ex-Dividend
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Fagron over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Fagron stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Fagron's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Fagron Stock Price History
DateFagron Price
8/6/202622.35 EUR
8/5/202622.45 EUR
8/4/202622.40 EUR
7/31/202623.20 EUR
7/30/202623.45 EUR
7/29/202623.40 EUR
7/28/202623.10 EUR
7/27/202623.15 EUR
7/24/202623.25 EUR
7/23/202623.55 EUR
7/22/202623.70 EUR
7/21/202623.85 EUR
7/20/202623.75 EUR
7/17/202623.90 EUR
7/16/202624.05 EUR
7/15/202624.10 EUR
7/14/202623.90 EUR
7/13/202623.95 EUR
7/10/202623.75 EUR
7/9/202623.95 EUR
7/8/202623.90 EUR
7/7/202624.05 EUR
7/6/202624.25 EUR
7/3/202624.50 EUR
7/2/202624.40 EUR
7/1/202624.00 EUR
6/30/202624.10 EUR
6/29/202623.85 EUR
6/26/202623.80 EUR
6/25/202623.95 EUR
6/24/202624.15 EUR
6/23/202624.05 EUR
6/22/202624.15 EUR
6/19/202624.00 EUR
6/18/202623.75 EUR
6/17/202623.75 EUR
6/16/202624.15 EUR
6/15/202624.80 EUR
6/12/202624.65 EUR
6/11/202624.80 EUR
6/10/202624.60 EUR
6/9/202624.40 EUR
6/8/202623.90 EUR
6/5/202623.85 EUR
6/4/202623.25 EUR
6/3/202623.15 EUR
6/2/202623.40 EUR
6/1/202623.85 EUR
5/29/202624.45 EUR
5/28/202624.70 EUR
5/27/202625.00 EUR
5/26/202625.20 EUR
5/25/202625.15 EUR
5/22/202624.85 EUR
5/21/202624.75 EUR
5/20/202624.60 EUR
5/19/202624.30 EUR
5/18/202624.05 EUR
5/15/202624.35 EUR
5/14/202623.90 EUR
5/13/202623.80 EUR
5/12/202623.85 EUR
5/11/202623.90 EUR
5/8/202624.60 EUR
5/7/202624.55 EUR
5/6/202624.85 EUR
5/5/202624.65 EUR
5/4/202624.10 EUR
4/30/202624.00 EUR
4/29/202624.00 EUR
4/28/202623.75 EUR
4/27/202623.65 EUR
4/24/202623.60 EUR
4/23/202623.60 EUR
4/22/202623.90 EUR
4/21/202623.80 EUR
4/20/202624.35 EUR
4/17/202624.40 EUR
4/16/202623.75 EUR
4/15/202623.35 EUR
4/14/202622.95 EUR
4/13/202622.80 EUR
4/10/202622.50 EUR
4/9/202622.50 EUR
4/8/202622.15 EUR
4/7/202621.98 EUR
4/2/202621.79 EUR
3/27/202621.21 EUR
3/26/202621.39 EUR
3/25/202621.73 EUR
3/24/202621.60 EUR
3/23/202621.80 EUR
3/20/202621.87 EUR
3/19/202622.38 EUR
3/17/202622.10 EUR
3/16/202622.03 EUR
3/13/202622.23 EUR
3/12/202622.17 EUR
3/11/202622.16 EUR
3/10/202622.53 EUR
3/9/202621.49 EUR
3/6/202621.82 EUR
3/5/202622.08 EUR
2/27/202622.65 EUR
2/26/202622.32 EUR
2/25/202622.13 EUR
2/23/202621.90 EUR
2/20/202622.40 EUR
2/19/202622.67 EUR
2/18/202622.93 EUR
2/17/202622.65 EUR
2/16/202622.48 EUR
2/13/202622.75 EUR
2/12/202623.29 EUR
2/11/202621.80 EUR
2/10/202622.00 EUR
2/9/202622.00 EUR
2/6/202622.21 EUR
2/5/202622.14 EUR
2/4/202622.00 EUR
2/3/202622.07 EUR
2/2/202622.12 EUR
1/30/202622.27 EUR
1/29/202622.37 EUR
1/28/202622.52 EUR
1/27/202623.09 EUR
1/26/202622.90 EUR
1/23/202622.82 EUR
1/22/202622.87 EUR
1/21/202622.36 EUR
1/20/202622.70 EUR
1/19/202622.58 EUR
1/16/202622.90 EUR
1/15/202622.10 EUR
1/14/202621.70 EUR
1/13/202621.78 EUR
1/12/202622.01 EUR
1/9/202622.04 EUR
1/8/202621.87 EUR
1/7/202622.02 EUR
1/6/202621.79 EUR
1/5/202621.80 EUR
1/2/202622.13 EUR
12/31/202521.35 EUR
12/30/202521.31 EUR
12/29/202521.25 EUR
12/24/202521.30 EUR
12/23/202521.25 EUR
12/22/202521.19 EUR
12/19/202521.29 EUR
12/18/202520.68 EUR
12/17/202520.41 EUR
12/16/202520.58 EUR
12/15/202520.62 EUR
12/12/202520.65 EUR
12/11/202520.46 EUR
12/10/202520.29 EUR
12/9/202520.35 EUR
12/8/202520.77 EUR
12/5/202520.87 EUR
12/4/202520.88 EUR
12/3/202520.86 EUR
12/2/202520.98 EUR
12/1/202521.12 EUR
11/28/202521.30 EUR
11/27/202521.34 EUR
11/26/202521.10 EUR
11/25/202521.21 EUR
11/24/202521.09 EUR
11/21/202520.64 EUR
11/20/202520.45 EUR
11/19/202520.35 EUR
11/18/202520.26 EUR
11/17/202520.40 EUR
11/14/202520.62 EUR
11/13/202520.70 EUR
11/12/202520.90 EUR
11/11/202520.69 EUR
11/10/202520.56 EUR
11/7/202520.55 EUR
11/6/202520.50 EUR
11/5/202520.42 EUR
11/4/202520.35 EUR
11/3/202520.35 EUR
10/31/202520.62 EUR
10/30/202520.62 EUR
10/29/202520.49 EUR
10/28/202520.41 EUR
10/27/202520.75 EUR
10/25/202520.87 EUR
10/23/202521.30 EUR
10/22/202521.06 EUR
10/21/202520.95 EUR
10/20/202520.96 EUR
10/17/202520.60 EUR
10/16/202520.62 EUR
10/15/202520.70 EUR
10/14/202520.83 EUR
10/13/202520.93 EUR
10/10/202521.00 EUR
10/9/202520.39 EUR
10/8/202520.22 EUR
10/7/202519.78 EUR
10/6/202519.93 EUR
10/3/202520.03 EUR
10/2/202519.80 EUR
10/1/202519.79 EUR
9/30/202519.78 EUR
9/29/202519.62 EUR
9/26/202519.64 EUR
9/25/202519.60 EUR
9/24/202519.60 EUR
9/23/202519.62 EUR
9/22/202519.88 EUR
9/19/202519.93 EUR
9/18/202519.59 EUR
9/17/202519.67 EUR
9/16/202519.85 EUR
9/15/202520.44 EUR
9/12/202520.80 EUR
9/11/202520.90 EUR
9/10/202520.71 EUR
9/9/202521.06 EUR
9/8/202521.02 EUR
9/5/202521.04 EUR
9/4/202521.10 EUR
9/3/202520.84 EUR
9/2/202520.75 EUR
9/1/202520.76 EUR
8/29/202520.80 EUR
8/28/202520.79 EUR
8/27/202520.54 EUR
8/26/202520.55 EUR
8/25/202520.65 EUR
8/22/202520.65 EUR
8/21/202520.55 EUR
8/20/202520.69 EUR
8/19/202520.73 EUR
8/18/202520.80 EUR
8/15/202520.73 EUR
8/14/202520.80 EUR
8/13/202520.80 EUR
8/12/202520.66 EUR
8/11/202520.90 EUR
8/8/202520.59 EUR
Access this data via the Eulerpool API
Get Free API Key

Fagron Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2022
683.88 M EUR
97.91 M EUR
69.61 M EUR
Jan 1, 2023
762.99 M EUR
108.63 M EUR
70.55 M EUR
Jan 1, 2024
871.96 M EUR
130.70 M EUR
80.55 M EUR
Jan 1, 2025
952.17 M EUR
139.42 M EUR
91.02 M EUR
Jan 1, 2026 (e)
1.14 B EUR
167.23 M EUR
107.39 M EUR
Jan 1, 2027 (e)
1.24 B EUR
182.48 M EUR
121.87 M EUR
Jan 1, 2028 (e)
1.35 B EUR
198.43 M EUR
138.99 M EUR
Jan 1, 2029 (e)
1.53 B EUR
225.26 M EUR
178.77 M EUR

Fagron Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 7, 2026, 7:33 PM
 
REVENUEB EUR
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM EUR
EBITM EUR
EBIT MARGIN%
NET INCOMEM EUR
NET INCOME GROWTH%
DIV.EUR
DIV. GROWTH%
SHARESM
2014201520162017201820192020202120222023202420252026e2027e2028e2029e
0.450.470.420.440.470.530.560.570.680.760.870.951.141.241.351.53
15.805.59-10.813.568.0313.383.933.2419.2011.5714.309.3019.548.619.2213.56
47.4346.4043.7143.3544.1644.9444.3243.1141.8743.5745.3521.4321.4321.4321.4321.43
212.00219.00184.00189.00208.00240.00246.00247.00286.00332.00395.00204.00243.86264.86289.29328.50
94.00-150.0017.0074.0073.0084.0088.0087.0097.00108.00130.00139.00167.00182.00198.00225.00
21.03-31.784.0416.9715.5015.7315.8615.1814.2014.1714.9314.6014.6714.7214.6714.68
16.00-202.00-20.0046.0042.0055.0059.0061.0069.0070.0080.0091.00107.00121.00138.00178.00
-150.00-1,362.50-90.10-330.00-8.7030.957.273.3913.111.4514.2913.7517.5813.0814.0528.99
0.721.00––0.100.120.080.180.200.250.300.350.420.500.60–
20.0038.89–––20.00-33.33125.0011.1125.0020.0016.6720.0019.0520.00–
31.2831.7070.9871.7471.9473.3972.3072.8672.8973.0372.8973.2173.2173.2173.2173.21
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Fagron generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Fagron retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Fagron's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Fagron has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Fagron's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Fagron stock margins

The Fagron margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Fagron. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Fagron.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
43.13 %
15.24 %
10.63 %
Jan 1, 2022
41.84 %
14.32 %
10.18 %
Jan 1, 2023
43.59 %
14.24 %
9.25 %
Jan 1, 2024
45.38 %
14.99 %
9.24 %
Jan 1, 2025
21.50 %
14.64 %
9.56 %
Jan 1, 2026 (e)
21.50 %
14.69 %
9.43 %
Jan 1, 2027 (e)
21.50 %
14.75 %
9.85 %
Jan 1, 2028 (e)
21.50 %
14.69 %
10.29 %

Fagron Stock Revenue, EBIT, Earnings per Share

The Fagron earnings per share therefore indicates how much revenue Fagron has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
7.88 EUR
1.20 EUR
0.84 EUR
Jan 1, 2022
9.38 EUR
1.34 EUR
0.96 EUR
Jan 1, 2023
10.45 EUR
1.49 EUR
0.97 EUR
Jan 1, 2024
11.96 EUR
1.79 EUR
1.11 EUR
Jan 1, 2025
13.01 EUR
1.90 EUR
1.24 EUR
Jan 1, 2026 (e)
15.56 EUR
2.28 EUR
1.47 EUR
Jan 1, 2027 (e)
16.91 EUR
2.49 EUR
1.67 EUR
Jan 1, 2028 (e)
18.46 EUR
2.71 EUR
1.90 EUR

Fagron business model & stock analysis

Fagron NV is an internationally operating company that focuses on the development and production of customized medications for pharmacies and hospitals. The company was founded in 1990 in Rotterdam, Netherlands. The beginnings of Fagron NV were in the Netherlands, where the company was established as Roterodamum Chemie BV. In the late 1990s, the company was converted into a holding company called Arseus NV, which later received the name Fagron. In 2012, Fagron was listed on the Euronext stock exchange in Brussels. Fagron operates globally and has locations in Europe, North America, Latin America, the United Arab Emirates, Asia, and Australia. Fagron's business model is based on the production of specialized medications for individual patient needs. The company offers a wide range of pharmaceutical active ingredients, raw materials, and processing services. There is also the possibility to develop and manufacture customized formulations tailored to the needs of patients. Fagron not only manufactures customized medications but also provides training and support for pharmacies and hospitals. Fagron operates in three main divisions: Specialty Pharma (hospital care), Community Pharma (prescription and non-prescription medications), and Compounding Services (custom formulations). The Specialty Pharma division specializes in medications for use in hospitals. It offers a wide range of products that can be used in the treatment of conditions such as cancer, HIV, and tuberculosis. These medications are manufactured in various dosage forms, such as injections, infusions, and tablets. The Community Pharma division focuses on prescription and non-prescription medications. Both branded and generic medications are offered. These are delivered directly to pharmacies, hospitals, and clinics. The Compounding Services division specializes in the production of customized medications. Fagron works closely with pharmacies and hospitals to meet individual needs. This includes, for example, the manufacture of medications in specific dosages or the combination of several active ingredients in a custom formulation. Fagron offers a wide range of products, including hormones, pain medications, cancer drugs, medications for the treatment of skin diseases, ophthalmic products, and anti-infectives. Pharmaceutical active ingredients and raw materials are also offered. Overall, Fagron is a global leader in the production of customized medications. It has extensive experience and expertise in the manufacturing of pharmaceutical formulations and offers a wide range of products and services. The various divisions of Fagron allow the company to meet the diverse needs of its customers and maintain its position as a leading company in the pharmaceutical industry.

Fagron SWOT Analysis

Strengths

Fagron NV possesses several key strengths that contribute to its success in the market. Firstly, the company has established a strong reputation as a leader in pharmaceutical compounding, offering customized medication solutions to healthcare providers. This expertise and experience provide Fagron NV with a competitive advantage over its rivals.

Another strength of Fagron NV lies in its global presence and widespread distribution network. The company operates in various countries, enabling it to reach a diverse range of customers and expand its market share. This international reach helps Fagron NV to mitigate risks associated with regional market fluctuations.

Weaknesses

Despite its strengths, Fagron NV also faces certain weaknesses that could hinder its growth potential. One such weakness is its reliance on external suppliers for raw materials. Any disruptions in the supply chain could affect the company's ability to fulfill customer orders, potentially leading to customer dissatisfaction and loss of market share.

Additionally, Fagron NV operates in a highly regulated industry, subject to strict compliance requirements. This can pose challenges in terms of additional costs for regulatory compliance and potential restrictions on product innovation and development. These factors may limit the company's ability to quickly respond to market changes or introduce new product lines.

Opportunities

Fagron NV has several opportunities it can capitalize on to further enhance its position in the market. One such opportunity lies in the growing demand for personalized medication solutions. As the healthcare industry continues to evolve, there is an increasing focus on individualized treatment options. Fagron NV can leverage its expertise in pharmaceutical compounding to cater to this emerging market segment.

Another opportunity for Fagron NV lies in expanding its product portfolio to include complementary healthcare products. By diversifying its offerings, the company can tap into new customer segments and revenue streams. This expansion can be achieved through strategic partnerships or acquisitions of established brands in the complementary healthcare sector.

Threats

Fagron NV is not immune to threats that may impact its business operations. One major threat is the increasing competition in the pharmaceutical compounding industry. The market is witnessing the entry of new players, both domestic and international, who aim to take advantage of the growing demand for personalized medication. Fagron NV must stay vigilant and continuously innovate to maintain its competitive edge.

Additionally, changes in government regulations and healthcare policies can pose threats to Fagron NV's operations. Alterations in reimbursement policies or drug pricing regulations can impact the company's profitability and pricing strategy. Fagron NV must closely monitor and adapt to any regulatory changes to mitigate potential risks.

Fagron Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Fagron historical P/E ratio, EBIT multiple, and P/S ratio

Fagron annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Fagron shares outstanding

The number of shares of Fagron was 73.21 M in 2025. This indicates how many shares Fagron is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
72.86 M Stocks
Jan 1, 2022
72.89 M Stocks
Jan 1, 2023
73.03 M Stocks
Jan 1, 2024
72.89 M Stocks
Jan 1, 2025
73.21 M Stocks
Jan 1, 2026 (e)
73.21 M Stocks
Jan 1, 2027 (e)
73.21 M Stocks
Jan 1, 2028 (e)
73.21 M Stocks

Fagron Dividend History

16 years of dividend payments · 5 consecutive increases

YearAnnual DividendYoY ChangePayments
20250.35EUR↑ 16.7%1×
May 19, 20250.35EUR↑ 16.7%1/1
20240.30EUR↑ 20.0%1×
20230.25EUR↑ 25.0%1×
20220.20EUR↑ 11.1%1×
20210.18EUR↑ 125.0%1×
20200.08EUR↓ 33.3%1×
20190.12EUR↑ 20.0%1×
20180.10EUR↓ 90.0%1×
20151.00EUR↑ 38.9%1×
20140.72EUR↑ 20.0%1×

Fagron dividend history and estimates

In 2025, Fagron paid a dividend amounting to 0.35 EUR. Dividend means that Fagron distributes a portion of its profits to its owners.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details
Date
Dividend
Dividend (Estimate)
Jan 1, 2021
0.18 EUR
0.00 EUR
Jan 1, 2022
0.20 EUR
0.00 EUR
Jan 1, 2023
0.25 EUR
0.00 EUR
Jan 1, 2024
0.30 EUR
0.00 EUR
Jan 1, 2025
0.35 EUR
0.00 EUR
Jan 1, 2026 (e)
0.00 EUR
0.42 EUR
Jan 1, 2027 (e)
0.00 EUR
0.50 EUR
Jan 1, 2028 (e)
0.00 EUR
0.60 EUR

Fagron dividend payout ratio

In 2025, Fagron had a payout ratio of 28.15%. The payout ratio indicates the percentage of the company's profits that Fagron distributes as dividends.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Date
Payout ratio
Jan 1, 2021
21.50 %
Jan 1, 2022
20.94 %
Jan 1, 2023
25.88 %
Jan 1, 2024
27.14 %
Jan 1, 2025
28.15 %
Jan 1, 2026 (e)
28.61 %
Jan 1, 2027 (e)
30.25 %
Jan 1, 2028 (e)
31.83 %

Current Fagron forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
5.88 %
Buy
92.31 % (12)
Hold
7.69 % (1)
Sell
0.00 % (0)
12M Price Target
27.54
Last Price
22.35
Currency
EUR
12M Return Potential
23.22 %
LTM Return
0 %

Fagron Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
8/6/2020-EUR-287.25 MEUR-2020 Q2
2/13/2020-EUR-290.29 MEUR-2019 Q4
8/20/20100.35EUR-207.77 MEUR-2010 Q2
8/21/20090.35EUR-192.90 MEUR-2009 Q2
3/3/2009-EUR-183.71 MEUR-2008 Q4
8/26/20080.33EUR-172.96 MEUR-2008 Q2

EESG©

Eulerpool ESG Scorecard© for the Fagron stock

74/100
64
Environment
99
Social
60
Governance
E

Environment

20
Scope 1 - Direct Emissions3,871
Scope 2 - Indirect emissions from purchased energy9,246
Scope 3 - Indirect emissions within the value chain282,802
Total CO₂ emissions13,117
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees56.5
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Fagron shareholder structure

% Name
18.05737%
Goldman Sachs Asset Management B.V.
Goldman Sachs Asset Management B.V.
11.07639%
Active Ownership Capital S.à.r.l.
Active Ownership Capital S.à.r.l.
4.96622%
Mawer Investment Management Ltd.
Mawer Investment Management Ltd.
4.12839%
Fidelity Management & Research Company LLC
Fidelity Management & Research Company LLC
3.28891%
BNP Paribas Asset Management Belgium S.A.
BNP Paribas Asset Management Belgium S.A.
3.26767%
abrdn Investment Management Limited
abrdn Investment Management Limited
...

Fagron Beneficial Ownership Filings (SEC 13D/G)

Free Float
89.7%
Float Shares
-
Shares Outstanding
-

Fagron Executives and Management Board

13 members · avg. age 53 · 31 % women

RP

Mr. Rafael Padilla (47)

Chief Executive Officer, Executive Director · since 2017

2.66 M EUR

Management

KJ

Mrs. Karin de Jong (46)

Chief Financial Officer, Executive Director · since 2016

1.48 M EUR
VB

Ms. Vera Bakker (53)

Chief Operations Officer · since 2022

7,500.00 EUR
KK

Mr. Kostas Kouloridas

Area Leader, EMEA

–
GN

Mr. Geraldino Neder

Area Leader, Latin America

–
AP

Mr. Andrew Pulido

Area Leader, North America

–
JV

Mr. Johan Verlinden

Head - Legal and M&A

–

Board of Directors

KH

Mr. Koen Hoffman (57)

Independent Chairman of the Board - Representing AHOK BV

110,000.00 EUR
KR

Mr. Klaus Roehrig (48)

Non-Executive Director

54,400.00 EUR
AD

Mrs. Ann Desender (54)

Non-Executive Independent Director

52,000.00 EUR
EV

Ms. Els Vandecandelaere (54)

Non-Executive Independent Director - Permanent Representative of Els Vandecandelaere LLC

50,000.00 EUR
NS

Mr. Neeraj Sharma (53)

Non-Executive Independent Director

40,000.00 EUR
RH

Mr. Robert ten Hoedt (65)

Non-Executive Independent Director

40,000.00 EUR

Fagron Supply Chain

Fagron Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
2 companies
#Nameβ 1YTrend
1
Nuvo Pharmaceuticals
Supplier·Customer·Pharmaceuticals·CA
0.47
0.80
-0.15
-0.47
-0.46
—
—
2
NN Group
Supplier·Customer·Insurance·NL
0.19
-0.02
0.86
0.16
-0.39
-0.74
-0.34

Frequently asked questions about Fagron

The business model of Fagron NV is focused on compounding and distributing personalized pharmaceutical products to pharmacies, hospitals, and clinics. Fagron operates as a global pharmaceutical company, supplying high-quality ingredients, equipment, and guidance to healthcare professionals. By providing tailor-made medicines, Fagron ensures that patients receive customized treatments that best suit their specific needs. Through its innovation-driven approach, Fagron collaborates with healthcare providers to improve patient outcomes and enhance the overall quality of pharmaceutical care. With a strong emphasis on compounding expertise and a wide range of product offerings, Fagron NV positions itself as a trusted partner in the pharmaceutical industry.

Fagron NV is primarily active in the pharmaceutical industry.

The main competitors of Fagron NV in the market are Teva Pharmaceutical Industries Ltd., Baxter International Inc., and McKesson Corporation.

Fagron NV, a renowned company in the stock market, has a rich history and background. Initially established in 1990, Fagron NV (previously known as Arseus NV) began its journey as a pharmaceutical wholesaler in Belgium. Over the years, the company evolved and expanded its focus towards compounding pharmacies globally, becoming a leading player in the compounding market. Fagron NV specializes in providing high-quality pharmaceutical ingredients, equipment, and innovative solutions to compounding professionals, enabling them to create tailored medications for their patients' unique needs. With a commitment to excellence and continuous growth, Fagron NV has become a trusted name in the pharmaceutical industry, offering comprehensive and reliable services worldwide.

Fagron NV has achieved several significant milestones in its history. The company has successfully expanded its global presence, becoming a leading player in the pharmaceutical compounding industry. Fagron NV has also demonstrated its commitment to innovation, developing advanced and personalized pharmaceutical solutions. Additionally, the company has achieved notable financial growth, consistently delivering strong financial performance over the years. Fagron NV's dedication to customer satisfaction and its continuous focus on quality have garnered it a solid reputation in the market. Overall, Fagron NV has a proven track record of success and remains at the forefront of the pharmaceutical industry.

Fagron NV is primarily present in a wide range of countries and regions across the globe. The company has a strong global presence, with operations in Europe, North America, South America, Asia-Pacific, and Africa. Fagron NV has established a strong foothold in various key markets, including the United States, Brazil, Belgium, the Netherlands, Germany, France, Spain, South Africa, and more. With its extensive international presence, Fagron NV is well-positioned to cater to the diverse needs of customers in different parts of the world while driving growth and innovation within the pharmaceutical compounding industry.

Fagron NV is a leading pharmaceutical company that values innovation, quality, and patient care. With a strong corporate philosophy, Fagron NV is committed to providing personalized medication solutions that meet the unique needs of patients worldwide. With a focus on research and development, Fagron NV strives to deliver high-quality compounded pharmaceuticals through advanced technology and expertise. By emphasizing patient well-being and professional collaboration, Fagron NV aims to improve the quality of life for individuals and contribute to the overall advancement of healthcare. Through its dedication to values and corporate philosophy, Fagron NV has become a trusted name in the pharmaceutical industry.

Analysts currently set an average price target of 27.18 EUR for the Fagron stock (median: 27.54 EUR), implying +21.6 % versus the latest price. The consensus is based on 13 analyst ratings.

Fagron Analyst Price Targets 2026

13 analysts currently rate the Fagron stock: 12 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Fagron to generate revenue of 1.14 B EUR and earnings per share of 1.47 EUR.

Fagron Analyst Price Targets 2026

The Fagron share (FAGR.BR) is listed on 6 stock exchanges, including: Frankfurt (4A5.F), Düsseldorf (4A5.DU), London (0HNZ.L).

Fagron NV is an internationally operating company specializing in the production and distribution of pharmaceutical products and services. The company operates worldwide in over 30 countries and is based in the Netherlands.

The expected revenue of Fagron is 1.14 B EUR. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Fagron is 107.39 M EUR. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Fagron is currently 15.24. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Fagron stock.

The price-to-sales ratio (P/S) of Fagron is currently 1.44. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Fagron stock.

The Eulerpool Quality Score for Fagron is 7/10.

The ISIN of Fagron is BE0003874915. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Fagron is A0M103. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Fagron is FAGR.BR. The ticker symbol is used to trade Fagron shares on the stock exchange.

Over the past 12 months, Fagron paid a dividend of 0.35 EUR . This corresponds to a dividend yield of about 1.57 %. For the coming 12 months, Fagron is expected to pay a dividend of 0.50 EUR.

The current dividend yield of Fagron is 1.57 %.

Fagron pays a dividend, distributed in the months of , , , .

Fagron paid dividends every year for the past 8 years.

For the upcoming 12 months, dividends amounting to 0.50 EUR are expected. This corresponds to a dividend yield of 2.24 %.

Fagron is assigned to the 'Health' sector.

To receive the latest dividend of Fagron from amounting to 0.35 EUR, you needed to have the stock in your portfolio before the ex-date on .

The last dividend was paid out on .

In the year 2025, Fagron distributed 0.3 EUR as dividends.

The dividends of Fagron are distributed in EUR.

All fundamentals and in-depth analysis of Fagron

Our stock analysis for Fagron stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Fagron. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Fagron Stock
Fagron Revenue→
Fagron Stock
Fagron Net Income→
Fagron Stock
Fagron P/E→
Fagron Stock
Fagron P/S→
Fagron Stock
Fagron EBIT→
Fagron Stock
Fagron Dividend→
Fagron Stock
Fagron Directors Dealings→
Fagron Stock
Fagron Stocks→
Fagron Stock
Fagron Market capitalization→
Fagron Stock
Fagron Debt→
Fagron Stock
Fagron Liabilities→
Fagron Stock
Fagron Equity→
Fagron Stock
Fagron AAQS→
Fagron Stock
Fagron Employees→
Fagron Stock
Fagron ROE→
Fagron Stock
Fagron ROA→
Fagron Stock
Fagron ROCE→
Fagron Stock
Fagron News→
Fagron Stock
Fagron Analyst Price Targets→

Health Stocks

Falco Holdings CoFaes FarmaFamiCordFabino EnterprisesFamily Care HospitalsF D CFamon Awal Bros Sedaya Tbk PTEZZ Life Science HoldingsFaron Pharmaceuticals OyezCaretech CoFate TherapeuticsEyePointAll Stocks A–Z →